CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Functional interrogation uncovers a critical role for a high-plasticity cell state in lung adenocarcinoma.
Functional interrogation uncovers a critical role for a high-plasticity cell state in lung adenocarcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
可塑性——细胞经历表型转变的能力——驱动癌症进展和治疗耐药 1-3。迄今为止,由于缺乏对潜在机制的基本了解,针对癌症可塑性的策略尚未进入临床。最近的研究表明,实体瘤的可塑性集中在癌细胞的少数亚群中 4-6,但缺乏原位探究这种高可塑性细胞状态 (HPCS) 的功能研究。在这里,我们开发了小鼠模型,能够在体内检测、纵向谱系追踪和消融原发性肺肿瘤中的 HPCS。通过谱系追踪,我们发现 HPCS 细胞是去分化的,但具有很高的细胞状态转换能力,可原位产生早期肿瘤(分化)和晚期肺癌细胞状态。使用分泌的荧光素酶进行的纵向谱系追踪显示,与大量癌细胞或具有分化肺上皮特征的另一种确定的癌细胞状态相比,HPCS 衍生细胞具有较高的生长能力。早期肿瘤中自杀基因介导的 HPCS 消融可消除肿瘤进展。通过自杀基因或 HPCS 定向 CAR-T 细胞消融已形成肿瘤中的 HPCS 细胞可显着减轻肿瘤负荷,而消融分化的肺癌细胞状态则没有效果。
我们进一步证明 HPCS 会产生治疗抵抗细胞状态,而 HPCS 的消融消除了对化疗和癌蛋白靶向治疗的抵抗。有趣的是,类似 HPCS 的状态在上皮再生和多种其他组织的癌中普遍存在,揭示了可塑性程序的趋同。
我们的工作将 HPCS 确立为一个关键枢纽,能够实现癌细胞状态之间的相互转换,包括获得适应癌症治疗的状态。靶向肺癌和其他癌症中的 HPCS 可能会抑制癌症进展并消除治疗耐药性。
Plasticity-the ability of cells to undergo phenotypic transitions-drives cancer progression and therapy resistance 1-3 . To date, strategies targeting cancer plasticity have not advanced to the clinic due to a lack of fundamental understanding of the underlying mechanisms. Recent studies have suggested that plasticity in solid tumors is concentrated in a minority subset of cancer cells 4-6 , yet functional studies interrogating this high plasticity cell state (HPCS) in situ are lacking.
Here, we developed mouse models enabling detection, longitudinal lineage tracing, and ablation of the HPCS in autochthonous lung tumors in vivo . Using lineage tracing, we uncover the HPCS cells are dedifferentiated but possess high capacity for cell state transitions, giving rise to both early neoplastic (differentiated) and advanced lung cancer cell states in situ .
Longitudinal lineage tracing using secreted luciferases reveals HPCS-derived cells harbor high capacity for growth when compared to bulk cancer cells or another defined cancer cell state with features of differentiated lung epithelium. Suicide gene-mediated ablation of the HPCS in early neoplasias abrogates tumor progression. Ablating HPCS cells in established tumors by suicide gene or HPCS-directed CAR T cells robustly reduces tumor burden, whereas ablation of a differentiated lung cancer cell state had no effect.
We further demonstrate that the HPCS gives rise to therapy-resistant cell states, whereas ablation of the HPCS abrogates resistance to chemotherapy and oncoprotein-targeted therapy. Interestingly, an HPCS-like state is ubiquitous in regenerating epithelia and in carcinomas of multiple other tissues, revealing a convergence of plasticity programs.
Our work establishes the HPCS as a critical hub enabling reciprocal transitions between cancer cell states, including acquisition of states adapted to cancer therapies. Targeting the HPCS in lung cancer and in other carcinomas may suppress cancer progression and eradicate treatment resistance.
MEMBER ACCOUNT
登录成功会直接打开下一页。